logo

GlaxoSmithKline announces new drug application and phase III results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

The most commonly reported all-cause adverse events by patients receiving casopitant included neutropenia, alopecia and fatigue, and were generally balanced across treatment arms.(2)
Read Full Item
http://www.medicalnewstoday.com/articles/109209.php
Date
30th May 2008
Source
Medical News Today